Sugammadex, a promising reversal drug. a review of clinical trials

Reviews on Recent Clinical Trials

Volumn 6, Issue 3, 2011, Pages 250-255

  Makri, Ira ^a   Papadima, Artemisia ^a   Lafioniati, Aimilia ^b   Pappas, Apostolos B ^b   George, Karanikas ^c   Nikolaos, Koronakis E ^c   Ioannis, Chrysikos D ^c   Charalambos, Seretis ^b   Emmanuel, Lagoudianakis E ^b   Xanthos, Theodoros ^b   Papadimitriou, Lila ^b  

^a HIPPOKRATION HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c Second Department of Surgery   (Greece)

Author keywords

Anesthesia; Cyclodextrins; Drugs; Neuromuscular blocking agents; Sugammadex; Sugar molecules

Indexed keywords

CHOLINESTERASE INHIBITOR; EDROPHONIUM; INHALATION ANESTHETIC AGENT; INTRAVENOUS ANESTHETIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; NEOSTIGMINE; PROPOFOL; ROCURONIUM; SEVOFLURANE; SUGAMMADEX; SUXAMETHONIUM; VECURONIUM;

ABDOMINAL DISCOMFORT; ALLERGY; ANAPHYLAXIS; ANESTHESIA (SENSORY DYSFUNCTION); ANESTHETIC RECOVERY; ARTICLE; BISPECTRAL INDEX; BRADYCARDIA; BRONCHOSPASM; CLINICAL TRIAL (TOPIC); COUGHING; DIARRHEA; DIZZINESS; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHEMA; FEVER; HEADACHE; HEART ARREST; HUMAN; HYPOTENSION; KIDNEY FAILURE; MALIGNANT HYPERTHERMIA; MYALGIA; NAUSEA; NEUROMUSCULAR BLOCKING; OLIGURIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; TACHYCARDIA; VOMITING; XEROSTOMIA;

CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; GAMMA-CYCLODEXTRINS; HUMANS; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR NONDEPOLARIZING AGENTS;

EID: 80051731493     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/157488711796575559     Document Type: Article

References (64)

1. Perry J, Lee J, Wells G: Rocuronium versus succinylcholine for rapid sequence induction intubation. Cochrane Database Syst Rev 2003; CD002788.
2. Magorian T, Flannery KB, Miller RD. Comparison of rocuronium, succinylcholine, and vecuronium for rapid-sequence induction of anesthesia in adult patients. Anesthesiology 1993; 79: 913-918.
3. Sahar M, Siddik-Sayyid1, Samar K, et al. Excellent intubating conditions with remifentanil-propofol and either low-dose rocuronium or succinylcholine. Can J Anaesth 2009; 56: 483-488.
4. Mencke T, Echternach M, Kleinschmidt S, et al. Laryngeal morbidity and quality of tracheal intubation: A randomized controlled trial. Anesthesiology 2003; 98: 1049-1056.
5. Book WJ, Abel M, Eisenkraft JB. Adverse effects of depolarising neuromuscular blocking agents. Incidence, prevention and management. Drug Saf 1994; 10: 331-49.
6. Gronert GA. Succinylcholine-induced hyperkalemia and beyond 1975. Anesthesiology 2009; 111: 1372-1377.
7. Mirakhur RK, Dundee JW, Jones CJ, Coppel DL, Clarke RSJ. Reversal of neuromuscular blockade: dose determination studies with atropine and glycopyrrolate given before or in a mixture with neostigmine. Anesth Analg 1981; 60: 557-562.
8. Cozanitis DA, Dundee JW, Merrett JD, Jones CJ, Mirakhur RK. Evaluation of glycopyrrolate and atropine as adjuncts to reversal of non-depolarizing neuromuscular blocking agents in a 'true-to-life' situation. Br J Anaesth 1980; 52: 85-89.
9. Arbous MS, Meursing AE, van Kleef JW, et al. Impact of anesthesia management characteristics on severe morbidity and mortality. Anesthesiology 2005; 102: 257-268.
10. Pedersen T, Viby-Mogensen J, Ringsted C: Anaesthetic practice and postoperative pulmonary complications. Acta Anaesthesiol Scand 1992; 36: 812-818.
11. Berg H, Viby-Mogensen J, Roed J, et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications: A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand 1997; 41: 1095-1103.
12. Viby-Mogensen J, Jørgensen BC, Ørding H: Residual curarization in the recovery room. Anesthesiology 1979; 50: 539-541.
13. Murphy GS, Szokol JW, Marymont JH, Franklin M, Avram MJ, Vender JS: Residual paralysis at the time of tracheal extubation. Anesth Analg 2005; 100: 1840-5.
14. Shorten GD: Postoperative residual curarisation: Incidence, aetiology and associated morbidity. Anaesth Intensive Care 1993; 21: 782-789.
15. Hunter JM, Flockton EA. The doughnut and the hole: a new pharmacological concept for anaesthetics. Br J Anaesth 2006; 97: 123-126.
16. Cameron KS, Clark JK, Cooper A, et al. Modified gammacyclodextrins and their rocuronium complexes. Org Lett 2002; 4: 3403-3406.
17. Szente L, Szejtli J. Highly soluble cyclodextrin derivatives: chemistry, properties and trends in development. Adv Drug Deliv Rev 1999; 36: 17-28.
18. Sikharam S, Egan TD, Kern SE. Cyclodextrins as new formulation entities and therapeutic agents. Curr Opin Anaesthesiol 2005; 18: 392-395.
19. Adam JM, Bennett DJ, Bom A, et al. Cyclodextrin derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: Synthesis and structure-activity relationships. J Med Chem 2002; 45: 1806-1816.
20. Kopman AF. Sugammadex: a revolutionary approach to neuromuscular antagonism. Anesthesiology 2006; 104: 631-633.
21. Epemolu O, Bom A, Hope F, Mason R: Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology 2003; 99: 632-637.
22. Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg 2007; 104: 575-581.
23. Yang LP, Keam SJ. Sugammadex: a review of its use in anaesthetic practice. Drugs 2009; 69: 919-942.
24. Mirakhur RK. Sugammadex in clinical practice. Anaesthesia 2009; 64 Suppl 1: 45-54.
25. Plaud B. Sugammadex: something new to improve patient safety or simply a gadget? Ann Fr Anesth Reanim 2009; 28 Suppl 2: S64-9.
26. Meistelman C, Fuchs-Buder T. Pharmacology of sugammadex. Ann Fr Anesth Reanim 2009; 28 Suppl 2: S51-6.
27. Debaene B, Meistelman C. Indications and clinical use of sugammadex. Ann Fr Anesth Reanim. 2009; 28 Suppl 2: S57-63.
28. Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 2002; 41: 266-70.
29. Epemolu O, Mayer I, Hope F, Scullion P, Desmond P. Liquid chromatography/ mass spectrometric bioanalysis of a modified cyclodextrin (Org 25969) and rocuronium bromide (Org 9426) in guinea pig plasma and urine: Its application to determine the plasma pharmacokinetics of Org 25969. Rapid Commun Mass Spectrom 2002; 16: 1946-1952.
30. de Boer HD, van Egmond J, van de Pol F, et al. Chemical encapsulation of rocuronium by synthetic cyclodextrin derivatives: reversal of neuromuscular block in anaesthetized Rhesus monkeys. Br J Anaesth 2006; 96: 201-206.
31. de Boer HD, van Egmond J, van de Pol F, et al. Reversal of profound rocuronium neuromuscular blockade by sugammadex in anesthetized Rhesus monkeys. Anesthesiology 2006; 104: 718-723.
32. de Boer HD, van Egmond J, van de Pol F, Bom A, Driessen JJ, Booij LH. Time course of action of sugammadex (Org 25969) on rocuronium-induced block in the Rhesus monkey, using a simple model of equilibration of complex formation. Br J Anaesth 2006; 97: 681-686.
33. Gijsenbergh F, Ramael S, Houwing N, van Iersel T. First human use of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005; 103: 695-703.
34. Cammu G, De Kam PJ, Demeyer I, et al. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers. Br J Anaesth 2008; 100: 373-379.
35. Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuroniuminduced neuromuscular block by the selective relaxant binding agent sugammadex: A dose-finding and safety study. Anesthesiology 2006; 104: 667-674.
36. Suy K, Morias K, Hans P, et al. Fast, effective and safe reversal of rocuronium and vecuronium-induced moderate neuromuscular block by the selective relaxant binding agent Org 25969. Anesthesiology 2005; 103: A1119.
37. Pühringer, F, Blaszyk, M, Cammu, G, Sparr, H, Heeringa M. Sugammadex achieves fast recovery from shallow neuromuscular blockade induced by rocuronium or vecuronium: dose-response studies: 9AP2-5 Euro J Anaesthesiol 2007; 24; 111.
38. Xue FS, Liao X, Tong SY, Liu JH, An G, Luo LK. Dose-response and time-course of the effect of rocuronium bromide during sevoflurane anaesthesia. Anaesthesia 1998; 53: 25-30.
39. Veiga-Ruiz G, Domínguez N, Orozco J, Janda M, Hofmockel R, Alvarez-Gómez JA. Efficacy of sugammadex in the reversal of neuromuscular blockade induced by rocuronium in long-duration surgery: under inhaled vs. intravenous anesthesia. Rev Esp Anestesiol Reanim 2009; 56: 349-354.
40. Rex C, Wagner S, Spies C, et al. Reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients randomized to sevoflurane or propofol maintenance anesthesia. Anesthesiology 2009; 111: 30-35.
41. Vanacker BF, Vermeyen KM, Struys MRF, et al. Reversal by Org 25969 is not affected by sevoflurane compared with propofol. Eur J Anaesthesiol 2005; 22: A453.
42. Shields M, Giovannelli M, Mirakhur RK, Moppett I, Adams J, Hermens Y. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth 2006; 96: 36-43.
43. Groudine SB, Soto R, Lien C, Drover D, Roberts K: A randomized, dosefinding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuroniuminduced neuromuscular block. Anesth Analg 2007; 104: 555-562.
44. Sparr HJ, Vermeyen KM, Beaufort AM, et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study. Anesthesiology 2007; 106: 935-943.
45. de Boer HD, Driessen JJ, Marcus MA, Kerkkamp H, Heeringa M, Klimek M. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex. A multicenter, dose-finding and safety study. Anesthesiology 2007; 107: 239-244.
46. Pühringer FK, Rex C, Sielenkämper AW, et al. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology 2008; 109: 188-197.
47. Khuenl-Brady K, Rex C, Sielenkämper A, et al. Reversal of highdose rocuronium with Org 25969. Eur J Anaesthesiol 2005; 22 (suppl 34): A458.
48. Duvaldestin P, Kuizenga K, Saldien V, et al. A randomized, doseresponse study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia. Anesth Analg 2010; 110: 74-82.
49. Williamson RM, Mallaiah S, Barclay P. Rocuronium and sugammadex for rapid sequence induction of obstetric general anaesthesia. Acta Anaesthesiol Scand. 2011 Apr 11. doi: 10.1111/j.1399- 6576.2011.02431.x. [Epub ahead of print].
50. Lee C, Jahr JS, Candiotti K, Warriner B, Zornow MH. Reversal of profound rocuronium NMB with sugammadex is faster than recovery from succinylcholine. Anesthesiology 2007; 107: A988.
51. Khuenl-Brady KS, Wattwil M, Vanacker BF, Lora-Tamayo JI, Rietbergen H, Alvarez-Gómez JA. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesth Analg 2010; 110: 64-73.
52. Blobner M, Eriksson L, Scholz J, Hillebrand H, Pompei L. Sugammadex (2.0 mg/kg) significantly faster reverses shallow rocuronium- induced neuromuscular blockade compared with neostigmine (50 mg/kg). Eur J Anaesth 2007; 24: 125.
53. Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology 2008; 109: 816-824.
54. Lemmens HJM, El-Orbany MI, Berry J, Martin G. Sugammadex reverses profound vecuronium blockade more rapidly than neostigmine. Anesthesiology 2007; 107: A1578.
55. Sacan O, White PF, Tufanogullari B, Klein K. Sugammadex reversal of rocuronium-induced neuromuscular blockade: A comparison with neostigmineglycopyrrolate and edrophonium-atropine. Anesth Analg 2007; 104: 569-574.
56. Illman HL, Laurila P, Antila H, Meretoja OA, Alahuhta S, Olkkola KT. The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train-of-four monitoring. Anesth Analg 2011; 112: 63-68.
57. Hoshi H, Kadoi Y, Kamiyama J, Nishida A, Saito H, Taguchi M, Saito S. Use of rocuronium-sugammadex, an alternative to succinylcholine, as a muscle relaxant during electroconvulsive therapy. J Anesth 2011; 25: 286-290.
58. Plaud B, Meretoja O, Hofmockel R, et al. Reversal of rocuroniuminduced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology 2009;110: 284-294.
59. McDonagh DL, Benedict PE, Kovac AL, et al. Efficacy and safety of sugammadex for reversal of rocuronium-induced blockade in elderly. Anesthesiology 2011; 114: 318-329.
60. Staals LM, Snoeck MM, Driessen JJ, van Hamersvelt HW, Flockton EA, van den Heuvel MW. Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. Br J Anaesth 2010; 104: 31-39.
61. Dahl V, Pendeville PE, Hollmann MW, Heier T, Abels EA, Blobner M. Safety and efficacy of sugammadex for the reversal of rocuronium- induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery. Eur J Anaesthesiol 2009; 26: 874-884.
62. Amao R, Zornow M, McTaggart-Cowan HM, Cheng D, Allard M. Sugammadex safely reverses rocuronium-induced blockade in patients with pulmonary disease. Anesthesiology 2007; 107: A1582.
63. White PF, Watcha MF. Pharmacoeconomics in anaesthesia: what are the issues? Eur J Anaesthesiol (Suppl) 2001; 23: 10-15.
64. Chambers D, Paulden M, Paton F. Sugammadex for the reversal of muscle relaxation in general anaesthesia: a systematic review and economic assessment. Health Technol Assess 2010; 14: 1-211.